Cargando…

Efficacy of in vitro treatment of chronic myelogenous leukemia cell line, K562 cells, using 4-hydroperoxycyclophosphamide, alpha-interferon and gamma-interferon.

Alpha-interferon (alpha-IFN) and gamma-interferon (gamma-IFN) are highly effective biologic agents in the treatment of chronic myelogenous leukemia (CML). 4-hydroperoxycyclophosphamide (4-HC) is the most commonly used chemotherapeutic drug when purging bone marrow contaminated with malignant cells....

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, J. T., Park, S., Lee, J. H., Kim, B. K., Kim, N. K.
Formato: Texto
Lenguaje:English
Publicado: Korean Academy of Medical Sciences 1996
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3053917/
https://www.ncbi.nlm.nih.gov/pubmed/8703367
_version_ 1782199840766164992
author Lee, J. T.
Park, S.
Lee, J. H.
Kim, B. K.
Kim, N. K.
author_facet Lee, J. T.
Park, S.
Lee, J. H.
Kim, B. K.
Kim, N. K.
author_sort Lee, J. T.
collection PubMed
description Alpha-interferon (alpha-IFN) and gamma-interferon (gamma-IFN) are highly effective biologic agents in the treatment of chronic myelogenous leukemia (CML). 4-hydroperoxycyclophosphamide (4-HC) is the most commonly used chemotherapeutic drug when purging bone marrow contaminated with malignant cells. To investigate the efficacy of alpha-IFN, gamma-IFN and 4-HC as purging agents in CML patients, K562 cells, a human CML cell line, were treated in vitro with these drugs singly or in combination. The cytotoxic effect was evaluated by MTT assay. Data were analyzed for synergism by the median effect principle of Chou and Talalay. Using Southern blot analysis, the effect of purging on the suppression of bcr gene rearrangement was also evaluated. Alpha-IFN, gamma-IFN and 4-HC all showed good concentration-dependent cytotoxic effect. Median cytotoxic doses of alpha-IFN gamma-IFN and 4-HC were 0.03 microM 0.20 microM and 1.97 microM respectively, and molar ratios of median doses of alpha-IFN to 4-HC, gamma-IFN to 4-HC and alpha-IFN to gamma-IFN were 1:80, 1:10 and 1:8, respectively. The combination treatment of alpha-IFN and 4-HC, and gamma-IFN and 4-HC showed significant synergistic cytotoxic activities, but combination of alpha-IFN and gamma-IFN was antagonistic. Status of bcr gene rearrangements in K562 cells was not changed after the treatments. Our results appear to provide an efficient method for removing CML cells from the bone marrow of CML patients.
format Text
id pubmed-3053917
institution National Center for Biotechnology Information
language English
publishDate 1996
publisher Korean Academy of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-30539172011-03-15 Efficacy of in vitro treatment of chronic myelogenous leukemia cell line, K562 cells, using 4-hydroperoxycyclophosphamide, alpha-interferon and gamma-interferon. Lee, J. T. Park, S. Lee, J. H. Kim, B. K. Kim, N. K. J Korean Med Sci Research Article Alpha-interferon (alpha-IFN) and gamma-interferon (gamma-IFN) are highly effective biologic agents in the treatment of chronic myelogenous leukemia (CML). 4-hydroperoxycyclophosphamide (4-HC) is the most commonly used chemotherapeutic drug when purging bone marrow contaminated with malignant cells. To investigate the efficacy of alpha-IFN, gamma-IFN and 4-HC as purging agents in CML patients, K562 cells, a human CML cell line, were treated in vitro with these drugs singly or in combination. The cytotoxic effect was evaluated by MTT assay. Data were analyzed for synergism by the median effect principle of Chou and Talalay. Using Southern blot analysis, the effect of purging on the suppression of bcr gene rearrangement was also evaluated. Alpha-IFN, gamma-IFN and 4-HC all showed good concentration-dependent cytotoxic effect. Median cytotoxic doses of alpha-IFN gamma-IFN and 4-HC were 0.03 microM 0.20 microM and 1.97 microM respectively, and molar ratios of median doses of alpha-IFN to 4-HC, gamma-IFN to 4-HC and alpha-IFN to gamma-IFN were 1:80, 1:10 and 1:8, respectively. The combination treatment of alpha-IFN and 4-HC, and gamma-IFN and 4-HC showed significant synergistic cytotoxic activities, but combination of alpha-IFN and gamma-IFN was antagonistic. Status of bcr gene rearrangements in K562 cells was not changed after the treatments. Our results appear to provide an efficient method for removing CML cells from the bone marrow of CML patients. Korean Academy of Medical Sciences 1996-02 /pmc/articles/PMC3053917/ /pubmed/8703367 Text en
spellingShingle Research Article
Lee, J. T.
Park, S.
Lee, J. H.
Kim, B. K.
Kim, N. K.
Efficacy of in vitro treatment of chronic myelogenous leukemia cell line, K562 cells, using 4-hydroperoxycyclophosphamide, alpha-interferon and gamma-interferon.
title Efficacy of in vitro treatment of chronic myelogenous leukemia cell line, K562 cells, using 4-hydroperoxycyclophosphamide, alpha-interferon and gamma-interferon.
title_full Efficacy of in vitro treatment of chronic myelogenous leukemia cell line, K562 cells, using 4-hydroperoxycyclophosphamide, alpha-interferon and gamma-interferon.
title_fullStr Efficacy of in vitro treatment of chronic myelogenous leukemia cell line, K562 cells, using 4-hydroperoxycyclophosphamide, alpha-interferon and gamma-interferon.
title_full_unstemmed Efficacy of in vitro treatment of chronic myelogenous leukemia cell line, K562 cells, using 4-hydroperoxycyclophosphamide, alpha-interferon and gamma-interferon.
title_short Efficacy of in vitro treatment of chronic myelogenous leukemia cell line, K562 cells, using 4-hydroperoxycyclophosphamide, alpha-interferon and gamma-interferon.
title_sort efficacy of in vitro treatment of chronic myelogenous leukemia cell line, k562 cells, using 4-hydroperoxycyclophosphamide, alpha-interferon and gamma-interferon.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3053917/
https://www.ncbi.nlm.nih.gov/pubmed/8703367
work_keys_str_mv AT leejt efficacyofinvitrotreatmentofchronicmyelogenousleukemiacelllinek562cellsusing4hydroperoxycyclophosphamidealphainterferonandgammainterferon
AT parks efficacyofinvitrotreatmentofchronicmyelogenousleukemiacelllinek562cellsusing4hydroperoxycyclophosphamidealphainterferonandgammainterferon
AT leejh efficacyofinvitrotreatmentofchronicmyelogenousleukemiacelllinek562cellsusing4hydroperoxycyclophosphamidealphainterferonandgammainterferon
AT kimbk efficacyofinvitrotreatmentofchronicmyelogenousleukemiacelllinek562cellsusing4hydroperoxycyclophosphamidealphainterferonandgammainterferon
AT kimnk efficacyofinvitrotreatmentofchronicmyelogenousleukemiacelllinek562cellsusing4hydroperoxycyclophosphamidealphainterferonandgammainterferon